Clinical Trial Update: RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update involving RC48 plus AK105 and cisplatin in advanced gastric cancer, including HER2-positive cases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastric Carcinoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• CISPLATIN (cisplatin)
• RC48 (disitamab vedotin)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Advanced Gastric Carcinoma, HER2-positive Gastric Cancer | Phase 2 | Status: UNKNOWN